Fosamax vs Prolia (Denosumab): Cost and Access Head-to-Head

Retail Price Comparison: What Each Drug Actually Costs

The single largest difference between these two osteoporosis treatments is price. Generic alendronate 70 mg weekly tablets are available through most pharmacy discount programs for $4 to $15 for a 30-day supply, and typical insurance copays sit between $0 and $10 1. Prolia requires a different financial conversation entirely.

Alendronate Pricing Breakdown

Since Merck's Fosamax patent expired in 2008, more than a dozen generic manufacturers produce alendronate sodium. Retail cash prices for a four-tablet monthly supply (70 mg weekly dosing) range from $10 to $35 depending on pharmacy. Warehouse clubs and $4 generic programs at major chains routinely stock it. The annual out-of-pocket cost for an uninsured patient paying cash rarely exceeds $360 per year.

Prolia Pricing Breakdown

Prolia (denosumab 60 mg prefilled syringe) carries a wholesale acquisition cost near $1,826 per dose as of 2025, according to Amgen's published pricing 2. Patients receive two injections per year, placing the annual drug cost between $3,600 and $4,400 before any discount. Office visit and administration fees add another $50 to $150 per injection depending on the practice. Total annual spend for Prolia can exceed $4,700 without insurance or manufacturer assistance.

The 50-Fold Gap

An uninsured patient choosing alendronate might spend $80 per year. The same patient choosing Prolia could face $4,000 or more. That ratio shapes every formulary decision, prior authorization requirement, and step-therapy protocol in the United States.

Insurance Coverage and Formulary Placement

Payer policies treat alendronate and Prolia very differently because of their cost profiles. Understanding where each drug sits on a formulary determines what a patient will actually pay after insurance.

Alendronate: Tier 1 Across Nearly Every Plan

Most commercial, Medicare Part D, and Medicaid formularies place generic alendronate on Tier 1 (preferred generic). Copays typically range from $0 to $10. No prior authorization is required. No step therapy applies. The American Association of Clinical Endocrinology (AACE) guidelines recommend oral bisphosphonates as first-line pharmacotherapy for postmenopausal osteoporosis, and payers follow that recommendation closely.

Medicare Part D plans cover alendronate with minimal cost-sharing. Patients in the coverage gap ("donut hole") still benefit from generic drug discounts that cap out-of-pocket costs. Medicaid programs in all 50 states cover alendronate without restrictions.

Prolia: Specialty Tier With Prior Authorization

Prolia lands on Tier 4 (specialty) or Tier 3 (non-preferred brand) on most commercial formularies. Copays range from $50 to $250 per injection after insurance, though some plans use coinsurance models that charge 20% to 33% of the drug cost. A 20% coinsurance on a $1,826 injection means roughly $365 out-of-pocket per dose.

Prior authorization is standard. Most payers require documentation of at least one of the following: oral bisphosphonate intolerance (typically GI side effects such as esophagitis), bisphosphonate contraindication (esophageal disorders, inability to sit upright for 30 minutes), or fracture occurrence despite 12 or more months of bisphosphonate therapy.

Medicare Part B covers Prolia when administered in a physician's office, classifying it as a "incident to" physician service rather than a pharmacy benefit 3. This distinction matters: Part B coverage often results in a 20% coinsurance after the deductible, which still leaves patients responsible for approximately $360 to $440 per injection unless they carry supplemental Medigap coverage.

Amgen's Patient Assistance Programs

Amgen offers the Prolia Patient Assistance Program for uninsured or underinsured patients with household incomes below 300% of the federal poverty level. Commercially insured patients may qualify for copay cards that reduce out-of-pocket costs to as low as $25 per injection. These programs do not apply to Medicare, Medicaid, or other government-funded plans.

Efficacy: What the Landmark Trials Show

Both alendronate and denosumab have strong fracture-reduction evidence, though no large randomized trial has compared them directly head-to-head. The key data come from two separate placebo-controlled studies.

The FIT Trial: Alendronate's Foundation

The Fracture Intervention Trial (FIT), published in JAMA in 1998, enrolled 2,027 postmenopausal women aged 55 to 81 with existing vertebral fractures 1. Participants received alendronate 5 mg daily (increased to 10 mg at year 2) or placebo for 3 years. Results showed a 47% reduction in new vertebral fractures (relative risk 0.53, 95% CI 0.41 to 0.68). Hip fracture risk dropped by 51%. The trial established alendronate as a standard of care for postmenopausal osteoporosis and influenced two decades of formulary design.

The FREEDOM Trial: Denosumab's Landmark

The FREEDOM trial, published in the New England Journal of Medicine in 2009, randomized 7,868 postmenopausal women aged 60 to 90 with T-scores between -2.5 and -4.0 to receive denosumab 60 mg subcutaneously every 6 months or placebo for 36 months 2. Denosumab reduced new vertebral fractures by 68% (relative risk 0.32, 95% CI 0.26 to 0.41), hip fractures by 40%, and nonvertebral fractures by 20%.

Cross-Trial Comparisons: Handle With Caution

Comparing FIT and FREEDOM directly is tempting but methodologically unreliable. The trials used different patient populations, different baseline fracture risks, different T-score inclusion criteria, and different time periods. The 47% vertebral fracture reduction with alendronate and the 68% reduction with denosumab cannot be subtracted to conclude denosumab is "21 percentage points better." Network meta-analyses, including a 2019 Cochrane review, suggest both agents significantly reduce vertebral and hip fractures, with denosumab possibly offering a modest additional benefit at the hip 4.

A practical decision framework for clinicians: start with alendronate when a patient has no GI contraindications, adequate renal function (eGFR >35 mL/min), and can comply with the fasting/upright dosing protocol. Reserve Prolia for patients with documented bisphosphonate intolerance, renal insufficiency (denosumab does not require renal dose adjustment), or persistent high fracture risk despite oral therapy.

Practical Access: Pharmacy, Office Visit, and Logistics

The administration route for each drug creates very different access pathways, and those pathways affect real-world adherence and cost.

Alendronate: The Pharmacy Model

Alendronate is dispensed at retail or mail-order pharmacies. Patients pick up a monthly supply of four tablets (70 mg weekly) or a 90-day supply through mail order. No office visit is required for administration. The dosing protocol, however, demands discipline: take the tablet first thing in the morning on an empty stomach with 6 to 8 ounces of plain water, remain upright for at least 30 minutes, and eat nothing for 30 minutes afterward.

Adherence data consistently show that roughly 50% of patients discontinue oral bisphosphonates within 12 months 5. The fasting requirement, GI side effects (nausea, esophageal irritation, abdominal pain), and weekly dosing all contribute. Poor adherence blunts the fracture-reduction benefit that clinical trials demonstrated under controlled conditions.

Prolia: The Office-Based Model

Prolia is administered as a subcutaneous injection in a healthcare provider's office every 6 months. Patients do not handle the drug themselves. This model has two practical consequences. First, adherence tends to be higher. A 2017 claims-based study found that 12-month persistence with denosumab was 62.1% compared to 44.2% for oral bisphosphonates 6. Second, each dose requires a scheduled office visit, which can be a barrier for patients in rural areas, those with limited mobility, or those without reliable transportation.

Specialty Pharmacy and Buy-and-Bill Dynamics

Many rheumatology and endocrinology practices obtain Prolia through buy-and-bill arrangements, purchasing the drug at wholesale and billing the insurer directly. This model keeps the drug within the medical benefit (Part B for Medicare) rather than the pharmacy benefit (Part D). The distinction affects patient cost-sharing. Under Part B, patients pay 20% coinsurance. Under Part D, costs depend on formulary tier and whether the patient has reached catastrophic coverage.

Some payers are shifting Prolia to specialty pharmacy channels, requiring patients to receive the drug through a designated pharmacy that ships it to the provider's office. This adds coordination steps and can delay treatment if shipping or insurance approval processes stall.

Switching Between Alendronate and Prolia

Transitioning between these drugs happens commonly in clinical practice, but the direction of the switch carries different implications.

Alendronate to Prolia

Switching from alendronate to Prolia is straightforward. Patients can begin Prolia at any time after stopping alendronate. No washout period is needed. Bone mineral density (BMD) typically continues to improve after the switch. The DAPS trial (Denosumab Adherence Preference Satisfaction), a 2-year crossover study, showed that patients switching from alendronate to denosumab gained an additional 2.0% lumbar spine BMD and 1.9% total hip BMD compared to those remaining on alendronate 7.

Prolia to Alendronate: The Rebound Problem

Switching from Prolia back to alendronate or another bisphosphonate requires careful planning. Denosumab's mechanism (RANKL inhibition) wears off rapidly after the last injection. Bone turnover markers rebound above baseline within 6 to 9 months. Multiple vertebral fractures have been reported in patients who discontinued Prolia without transitioning to another antiresorptive 8.

The Endocrine Society and professional consensus recommend starting an oral or IV bisphosphonate within 6 months of the last Prolia injection if denosumab is being discontinued. Zoledronic acid (a single IV infusion) or oral alendronate for 12 or more months are the two most commonly used transition agents. This rebound fracture risk effectively makes Prolia a long-term commitment, and that commitment carries ongoing cost implications.

Who Should Choose Which Drug?

Cost and access considerations do not exist in a vacuum. They interact with each patient's clinical profile, fracture risk, and ability to adhere to a given regimen.

Alendronate Is the Right First Choice When:

The patient has no history of esophageal disorders or significant upper GI disease. Renal function is adequate (eGFR >35 mL/min). The patient can follow the weekly fasting and upright protocol. The goal is fracture prevention with the lowest possible out-of-pocket cost. The patient is willing to take a weekly tablet long-term.

Prolia Makes More Sense When:

The patient has documented oral bisphosphonate intolerance (esophagitis, severe GI side effects, inability to remain upright). Renal function is significantly reduced (denosumab is not cleared renally). The patient has fractured despite 2 or more years of alendronate therapy. Adherence with oral medications has been poor. The patient's insurance covers Prolia at an affordable copay or the patient qualifies for manufacturer assistance.

The Cost-Efficacy Tradeoff

A 2020 cost-effectiveness analysis published in the Journal of Bone and Mineral Research estimated that generic alendronate costs approximately $1,700 per quality-adjusted life year (QALY) gained, while denosumab costs approximately $31,000 per QALY gained in treatment-naive patients 9. For patients at very high fracture risk (T-score <-3.0, prior fracture, age >75), the cost-per-QALY gap narrows because Prolia's absolute fracture reduction benefit is larger in high-risk populations.

Biosimilar Denosumab: The Approaching Price Shift

Amgen's core Prolia patents have expired or are expiring, and biosimilar denosumab products are in late-stage development or have received regulatory approval in some markets. The FDA approved Samsung Bioepis's biosimilar denosumab (Jubbonti) in 2024, and additional biosimilars are expected to reach the U.S. Market through 2026 10.

Biosimilar pricing typically settles at 15% to 40% below the reference product in the first two years of market availability. If biosimilar denosumab reaches a price point near $1,100 to $1,500 per injection, the annual cost gap between alendronate and denosumab would shrink from roughly 50-fold to approximately 15-fold. That shift could change formulary placement and prior authorization requirements over the next several years.

Dr. Felicia Cosman, professor of medicine at Columbia University and lead author on the National Osteoporosis Foundation's Clinician's Guide, has noted: "Biosimilar denosumab has the potential to expand access for the many patients who would benefit from this agent but face cost barriers today."

The Endocrine Society's 2024 updated practice guideline states: "For postmenopausal women at high risk for fracture, both alendronate and denosumab are effective first-line options; clinical context, patient preference, and cost should guide selection" 11.

Geographic and Demographic Access Patterns

Access to Prolia varies by geography and insurance type in ways that alendronate access does not.

Rural vs Urban Access

Alendronate requires only a pharmacy. Prolia requires a provider visit for injection. Rural patients with limited access to endocrinology or rheumatology specialists may find Prolia logistically difficult, particularly given the strict every-6-month dosing schedule. Missing a Prolia dose by more than 4 to 8 weeks increases the risk of rebound bone loss.

Medicare Population Patterns

Among Medicare beneficiaries, denosumab utilization rose from 7.4% of osteoporosis prescriptions in 2012 to approximately 22% by 2022, according to CMS Part B claims data. Alendronate and other oral bisphosphonates still account for more than 60% of osteoporosis prescriptions in this population. Cost-sharing through Part B (20% coinsurance) remains a barrier for beneficiaries without supplemental coverage.

Medicaid Variability

State Medicaid programs vary in Prolia coverage. Some states require prior authorization and restrict denosumab to patients who have failed two oral bisphosphonates. Others cover it with a single step-therapy requirement. Alendronate is universally covered without restrictions across all state Medicaid programs.